The enigma of recent onset dilated cardiomyopathy: What cause, what consequence, what control?

Canadian Journal of Cardiology

Volumn 16, Issue 5, 2000, Pages 641-652

  Chan, Albert W ^a   McManus, Bruce M ^a   Ignaszewski, Andrew P ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

Cardiomyopathy; Congestive heart failure; Diagnosis; Myocarditis

Indexed keywords

CARVEDILOL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE;

DYSPNEA; FATIGUE; HEART DILATATION; HUMAN; LEG EDEMA; LUNG EDEMA; NAUSEA; REVIEW; THORAX PAIN;

ACUTE DISEASE; ADULT; ALGORITHMS; ANTI-INFLAMMATORY AGENTS; BIOPSY; CARDIOMYOPATHY, DILATED; CARDIOVASCULAR AGENTS; DECISION TREES; DIAGNOSIS, DIFFERENTIAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEART CATHETERIZATION; HUMANS; MALE;

EID: 0034093156     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Heikkila J. Karjalainen J. Evaluation of mild acute infectious myocarditis. Br Heart J 1982;47:381-91.
2. Maze SS , Adolph RJ. Myocarditis: unresolved issues in diagnosis and treatment. Clin Cardiol 1990;13:69-79.
3. Kopecky SL, Gersh BJ. Dilated cardiomyopathy and myocarditis: natural history, etiology, clinical manifestations, and management. Curr Probl Cardiol 1987;12:569-647.
4. Bengtsson E, Lamberger B. Five-year follow-up study of cases suggestive of acute myocarditis. Am Heart J 1966;72:751-63.
5. Beck MA, Chapman NM, McManus BM, Mullican JC, Tracy S. Secondary enterovirus infection in the murine model of myocarditis. Pathol Immunol Aspects 1990;136:669-81.
6. Mason JW, O'Connell JB, Herskowit: A, et al. A clinical trial of immunosuppressive therapy tor myocarditis. N Engl J Med 1995;333:269-75.
7. ACC/AHA Task Force Report. Guidelines for the evaluation and management of heart failure. Circulation 1995;92:2764-84.
8. Braunwald E, Colucci W, Grossman W. Clinical aspects of heart failure: High-output heart failure; pulmonary edema. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia: WB Saunders, 1997:450-9.
9. Criteria Committe, New York Heart Association, Inc. Disease of the Heart and Blood Vessels. Nomenclature and Criteria for Diagnosis, 6th edn. Boston: Little, Brown, and Co, 1964:114.
10. Smith SC, Ladenson JH, Mason JW, Jaffe AS. Elevations of cardiac troponin I associated with myocarditis. Circulation 1997;95:163-8.
11. Morgera T, Di Lenarda A, Dreas L, et al. Electrocardiography of myocarditis revisited: clinical and prognostic significance of electrocardiographic changes. Am Heart J 1992;124:455-66.
12. Smith WG. Coxsackie B myopericarditis in adults. Am Heart J 1970;80:34-6.
13. Take M, Sekiguchi M, Hiroe M, Hirosawa K. Long-term follow-up of electrocardiographic findings in patients with acute myocarditis proven by endomocardial biopsy. Jpn Circ J 1982;46:1227-34.
14. Gerzen P, Granath A, Holmgren B, Zetterquist S. Acute myocarditis. A follow-up study. Br Heart J 1972;34:575-83.
15. Zipes DP. Specific arrhythmias: diagnosis and treatment. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia: WB Saunders, 1997:640-704.
16. Smith TW, Kelly RA, Stevenson LW, Braunwald E. Management of heart failure. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia: WB Saunders, 1997:492-514.
17. Olson LJ, Baldus WP, Tajik AJ. Echocardiographic features of idiopathic hemochromatosis. Am J Cardiol 1987;60:885-9.
18. Lewin RF, Mor R, Spitzer S, et al. Echocardiographic evaluation of patients with systemic sarcoidosis. Am Heart J 1985;110:116-22.
19. Dabestani A, Child JS, Henze E, et al. Primary hemochromatosis: anatomic and physiologic characteristics of the cardiac ventricles and their response to phlebotomy. Am J Cardiol 1984;54:153-9.
20. Klein AL, Oh JK, Miller FA, Seward JB, Tajik AJ. Two-dimensional and Doppler echocardiographic assessment of infiltrative cardiomyopathy. J Am Soc Echocardiogr 1988;1:48-59.
21. Jin O, Sole MJ, Butany JW. The detection of enterovirus RNA in myocardial biopsies from patients with myoarditis and cardiomyopathy using gene amplification by the polymerase chain reaction, Circulation 1990;82:8-16.
22. Martin AB, Webber S, Fricker FJ, et al. Acute myocarditis. Rapid diagnosis by PCR in children. Circulation 1994;90:330-9.
23. Koide H, Kitaura Y, Ukimura A, Kawamura K, Kirai K. Genomic detection of enteroviruses in the myocardium - studies on animal hearts with coxsackievirus B3 myocarditis and endomyocardial biopsies from patients with myocarditis and dilated cardiomyopathy. Jpn Circ J 1992;56:1081-93.
24. Bowles NE, Richardson PJ, Olsen EGJ, Archard LC. Detection of coxsackie B virus specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet 1986;i:1120-3.
25. Keeling PJ, Jeffrey S, Caforio AL, et al. Similar prevalence of enteroviral genome within the myocardium from patients with idiopathic dilated cardiomyopathy and controls by the polymerase chain reaction. Br Heart J 1992;68:554-9.
26. Grasso M, Arbustini E, Silini E, et al. Search for coxsackievirus B3 RNA in idiopathic dilated cardiomyopathy using gene amplification by polymerase chain reaction. Am J Cardiol 1992;69:658-64.
27. Kandolf R, Klingel K, Mertsching H, et al. Molecular studies on enteroviral heart disease: patterns of acute and persistent infections. Eur Heart J 1991;12(Suppl D):49D-55D.
28. Tracy S, Wiegand V, McManus B, et al. Molecular approaches to enteroviral diagnosis in idiopathic cardiomyopathy and myocarditis. J Am Coll Cardiol 1990;15:1688-94.
29. Parillo JE, Cunnion RE, Epstein SE, et al. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989;321:1061-8.
30. Jones SR, Herskowitz A, Hutchins GM, Baughman KL. Effects of immunosuppressive therapy in biopsy-proved myocarditis and borderline myocarditis on left ventricular function. Am J Cardiol 1991;68:370-6.
31. Hosenpud JD, McAnulty JH, Niles NR. Lack of objective improvement in ventricular systolic function in patients with myocarditis treated with azathioprine and prednisone. J Am Coll Cardiol 1985;6:797-801.
32. . Jonas M, Hod H. Is immunosuppressive treatment an option for myocarditis? Isr J Med Sci 1997;33:762-6.
33. Latham RD, Mulrow JP, Virmani R, Robinowitz M, Moody JM. Recently diagnosed idiopathic dilated cardiomyopathy: incidence of myocarditis and efficacy of prednisone therapy. Am Heart J 1989;117:876-82.
34. Unverferth DV, Magorien RD, Moeschberger ML, et al. Factors influencing the one-year mortality of dilated cardiomyopathy. Am J Cardiol 1984;54:147-52.
35. Schwarz F, Mall G, Zebe H, et al. Determinants of survival in patients with congestive cardiomyopathy: quantitative morphologic findings and left ventricular hemodynamics. Circulation 1984;70:923-8.
36. Why HJ, Meany BT, Richardson PJ, et al. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation 1994;89:2582-9.
37. McCarthy RE, Boehmer JP, Hruban RH, et al. Clinicopathologic classification of myocarditis predicts long-term outcome. 1st Annual Meeting of The Heart Failure Society of America. Baltimore, September 21 to 24, 1997.
38. Felker GM, Hu W, Hare JM, et al. Idiopathic cardiomyopathy is less idiopathic than you think: an endomyocardial biopsy study of 1278 patients. 3rd Annual Scientific Meeting of The Heart Failure Society of America. San Francisco, September 22 to 25, 1999.
39. Aretz HT, Billingham ME, Edwards WD, et al. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1987;1:3-14.
40. Fenoglio JJ, Ursell PC, Kellogg CF, Drusin RE, Weiss MB. Diagnosis and classification of myocarditis by endomyocardial biopsy. N Engl J Med 1983;308:12-8.
41. Klingel K, Hohenadl C, Canu A, et al. Ongoing enterovirus-induced myocarditis is associated with persistent heart mucsle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci USA 1992;89:314-8.
42. McNamara DM, Starling RC, Dec W, et al. Prevalence of myocarditis in acute dilated cardiomyopathy. 3rd Annual Scientific Meeting of The Heart Failure Society of America. San Francisco, September 22 to 25, 1999.
43. Hauck AJ, Keamey DL, Edwards WD. Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin Proc 1989;64:1235-45.
44. Chow LH, Radio SJ, Sears TD, McManus BM. Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J Am Coll Cardiol 1989;14:915-20.
45. Popma JJ, Cigarroa RG, Buja LM, Hillis LD. Diagnostic and prognostic utility of right-sided catheterization and endomyocardial biopsy in idiopathic dilated cardiomyopathy. Am J Cardiol 1989;63:955-8.
46. Hosenpud JD. Usefulness of endomyocardial biopsy in tertiary care. West J Med 1989;150:43-5.
47. Dec GW, Palacios I, Yasuda T, et al. Antimyosin antibody imaging: its role in the diagnosis of myocarditis. J Am Coll Cardiol 1990;16:97-104.
48. Dec GW, Palacios IF, Fallon JT, et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies. N Engl J Med 1985;312:885-9.
49. Reyes MP, Lerner MA. Coxsackievirus myocarditis - with special reference to acute and chronic effects. Prog Cardiovasc Dis 1985;27:373-94.
50. Woodroof JF. Viral myocarditis: a review. Am J Pathol 1980;101:427-79.
51. Rozkovec A, Cambridge G, King M, Hallidie-Smith KA. Natural history of left ventricular function in neonatal coxsackie myocarditis. Pediatr Cardiol 1985;6:151-6.
52. Suckling PV, Vogelpoel L. Coxsackie myocarditis of the newborn. Lancet 1970;ii:421.
53. Goren A, Kaplan M, Glaser J, Isacsohn M. Chronic neonatal coxsackie myocarditis. Arch Dis Child 1989;64:404-6.
54. Barbara G, Di Lorenzo G, Grisorio B, Barbarini G. Incidence of dilated cardiomyopathy and detection of HIV in myoardial cells of HIV-positive patients. N Engl J Med 1998;339:1093-9.
55. Matsumori A, Matoba Y, Sasayama S. Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation 1995;92:2519-25.
56. Okabe M, Fukuda K, Arakawa K, Kikuchi M. Chronic variant of ocarditis associated with hepatitis C virus infection. Circulation 1997;96:22-4.
57. Matsumori A. Molecular and immune mechanisms in the pathogenesis of cardiomyopathy: role of viruses, cytokines, and nitric oxide. Jpn Circ J 1997;61:275-91.
58. Lange LG, Schreiner GF. Immune mechanisms of cardiac disease. N Engl J Med 1994;330:1129-35.
59. Huber SA , Lodge PA. Coxsackie B-3 myocarditis in Balb/c mice. Evidence for autoimmunity to myocyte antigens. Am J Pathol 1984;116:21-9.
60. Lodge PA, Herzum M, Olszewski J, et al. Coxsackie B-3 myocarditis: acute and chronic forms of the disease caused by different immunopathogenic mechanisms. Am J Pathol 1987;128:455-63.
61. Neu N, Beisel KW, Traystman MD, et al. Autoantibodies specific for the cardiac myosin isoform are found in mice susceptible to coxsackie B3-induced myocarditis. J Immunol 1987;138:2488-92.
62. Liu P, Martino T, Opavsky MA, Penninger J. Viral myocarditis: Balance between viral infection and immune response. Can J Cardiol 1996;12:935-43.
63. Penninger JM, Pummerer C, Liu P, Neu N, Bachmaier K. Cellular and molecular mechanisms of murine autoimmune myocarditis. APMIS 1997;105:1-13.
64. McManus BM, Chow LH, Wilson JE, et al. Direct myocardial injury by enterovirus: a central role in the evolution of murine myocarditis. Clin Immunol Immunopathol 1993;68:159-69.
65. Chow LH. Studies of virus-induced myocardial injury in mice: value of the scid mutation on different genetic backgrounds and combined with other mutations. Lab Anim Sci 1993;43:133-5.
66. Chow LH, Beisel KW, McManus BM. Enteroviral infection of mice with severe combined immunodeficiency. Evidence for direct viral pathogenesis of myocardial injury. Lab Invest 1992;66:24-31.
67. Matsumori A, Yamada T, Suzuki H, et al. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994;72:561-6.
68. Toyozaki T, Saito T, Takano H, et al. Increased serum levels of circulating intercellular adhesion molecule-1 in patients with myocarditis. Circulation 1996;87:189-93.
69. Huber SA, Polgar J, Schultheiss P, Schwimmbeck P. Augmentation of pathogenesis of coxsackievirus B3 infections in mice by exogenous administration of interleukin-1 and interleukin-2. J Virol 1994;68:195-206.
70. Weisensee D, Bereiter-Han J, Schoeppe W, Low-Friedrick I. Effects of cytokines on the contractility of cultured cardiac myocytes. Int J Immunopharmacol 1993;15:581-7.
71. Yamada T, Matsumori A, Sasayama S. Therapeutic effect of anti-tumor necrosis factor-α antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation 1994;89:846-51.
72. Cooper LT, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis -natural history and treatment. N Engl J Med 1997;336:1860-6.
73. Davidoff R, Palacios I, Southern J, et al. Giant cell versus lymphocytic myocarditis, a comparison of their clinical features and long-term outcomes. Circulation 1991;83:953-61.
74. Litovsky SH, Burke AP, Virmani R. Giant cell myocarditis: an entity distinct from sarcoidosis characterized by multiphasic myocyte destruction by cytotoxic T cells and histiocytic giant cells. Mod Pathol 1996;9:1126-34.
75. Lemery R, McGoon MD, Edwards WD. Cardiac sarcoidosis: a potentially treatable form of myocarditis. Mayo Clin Proc 1985;60:549-54.
76. Gillete PC, Smith RT, Garson A, et al. Chronic supraventricular tachycardia: a curable cause of congestive cardiomyopathy. JAMA 1985;253:391-2.
77. Grogan M, Smith HC, Gersh BJ, et al. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992;69:1570-3.
78. Morishima I, Sassa H, Sone T, et al A case of fulminant myocarditis rescued - by long-term percutaneous cardiopulmonary support. Jpn Circ J 1994;58:433-8.
79. Yasu T, Murata S, Katsuki T, et al. Acutely severe myocarditis successfully treated by percutaneous cardiopulmonary support applied by a newly developed heparin-binding oxygenator and circuits. Jpn Circ J 1997;61:1037-42.
80. Moreno-Cabral CE, Moreno-Cabral RJ, McNamara JJ, Dembitsky WP, Adamson RM. Prolonged extracorporeal circulation for acute myocarditis. Int J Artif Organs 1992;15:475-80.
81. . Rezkalla SH, Raikar S, Kloner RA. Treatment of viral myocarditis with focus on captopril. Am J Cardiol 1996;77:634-7.
82. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
83. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
84. Cohn JN, Johnson G, Zeische S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
85. Poole-Wlson PA, Pitt B. ELITE II (Evaluation of Losartan in The-Elderly) Study - The Losartan Heart Failure Survival Study. 72nd Scientific Sessions of The American Heart Association. Atlanta, November 8 to 11, 1999.
86. Pitt R, Chang P, Grossman W, et al. Rationale, background, and design of the randomized angiotensin receptor antagonist-angiotensin converting enzyme inhibitor study (RAAS). Am J Cardiol 1996;78:1129-31.
87. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
88. Packer M, Carver JR, Rodeheffer RJ, et al. Prospective randomized milrinone survival evaluation trial. N Engl J Med 1991;325:1468-75.
89. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998;339:1810-6.
90. Bertram P, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
91. Dong R, Liu P, Wee L, Butany J, Sole MJ. Verapamil ameliorates the clinical and pathological course of murine myocarditis. J Clin Invest 1992;90:2022-30.
92. Puley G, Sole MJ, Dawood F, et al. Amlodipine improves mortality and function in a murine model of myocarditis-dilated cardiomyopathy: the role of microvascular blood flow. 2nd Annual Meeting of The Heart Failure Society of American. Boca Raton, September 13 to 16, 1998.
93. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.
94. CIBIS Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
95. Packer M, Bristow MR, Cohn JN, et al. US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
96. Rezkalla S, Kloner RA, Khatih G, Smith FE, Khatih R. Effect of metoprolol in acute coxsackievirus B3 murine myocarditis. J Am Coll Cardiol 1988;12:412-4.
97. Benigni A, Remuzzi G. Endothelin antagonists. Lancet 1999;353:133-8.
98. Mishima T, Tanimura M, Suzuki G, et al. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 2000;35:222-9.
99. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Contribution of endothelin-1 to myocardial injury in a murine model of myocarditis: acute effects or besentan, an endothelin receptor antagonist. Circulation 1999;100:1823-9.
100. Rezkalla SH, Kloner RA. Management strategies in viral myocarditis. Am Heart J 1989;117:706-8.
101. Peters NS, Poole-Wilson PA. Myocarditis - continuing clinical and pathologic confusion. Am Heart J 1991;121:942-7.
102. Olinde KD, O'Connell KB. Inflammatory heart disease: pathogenesis, clinical manifestations, and treatment of myocarditis. Annu Rev Med 1994;45:481-90.
103. Peters NS, Poole-Wilson PA. Myocarditis - a controversial disease. J R Soc Med 1991;84:1-2.
104. Khatib R, Reyes MP, Smith F, Khatib G, Rezkalla S. Enhancement of coxsackievirus B4 virulence by indomethacin. J Lab Clin Med 1990;115:116-20.
105. Rezkalla S, Khatib G, Khatib R. Coxsackievirus B3 murine myocarditis. Deleterious effects of nonsteroidal anti-inflammatory agents. J Lab Clin Med 1986;107:393-5.
106. Costanzo-Nordin MR, Reap EA, O'Connell JB, Robinson JA, Scanlon J. A nonsteroidal anti-inflammatory drug exacerbates coxsackievirus B3 murine myocarditis. J Am Coll Cardiol 1985;6:1078-82.
107. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death. Circulation 1999;99:1091-100.
108. Ray CG, Icenogle TB, Minnich LL, Copeland JG, Grogan TM. The use of intravenous ribavirin to treat influenza virus-associated acute myocarditis. J Infect Dis 1989;159:829-36.
109. Matsumori A, Wang H, Abelman WH, Crumpacker CS. Treatment of viral myocarditis with ribavirin in an animal preparation. Circulation 1985;71:834-9.
110. Kishimoto C, Crumpacker CS, Abelmann WH. Ribavirin treatment of murine coxsackevirus B3 myocarditis with analyses of lymphocyte subsets. J Am Coll Cardiol 1988;12:1334-41.
111. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999;282:1240-6.
112. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999;341:1336-43.
113. Drucker NA, Colan SD, Lewis AB, et al. Gamma-globuin treatment of acute myocarditis in the pediatric population. Circulation 1994;89:252-7.
114. McNamara DM, Rosenblum WD, Janosko KM, et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomopathy. Circulation 1997;95:2476-8.
115. Bozkurt B, Villaneuva FS, Holubkov R, et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol 1999;34:177-80.
116. McNamara DM, Starling RC, Dec GW, et al. Intervention in myocarditis and acute cardiomyopathy with immune globulin: results from the randomized placebo controlled IMAC trial. 72nd Scientific Sessions of the American Heart Association. Atlanta, November 8 to 11, 1999.
117. O'Connell JB, Dec GW, Goldenberg IF, et al. Results of heart transplantation for active lymphocytic myocarditis. J Heart Transplant 1990;9:351-5.